gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · VRTXHealthcarePharmaceuticals

Vertex Pharmaceuticals Inc (VRTX)

$549.04+3.44%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$549.88▲ 30.41% in range
Nov 4, 2025Low $409.47 · High $558.88Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Vertex Pharmaceuticals closed at $549.04 on Nov 4, up 3.44%, 1.8% below its 52-week closing high. Volume of 1.8M shares was 1.15× its 20-day average (close to normal).

Split-adjusted performance: +9.3% over one month, +28.4% over six months, +28.9% over one year.

In the quarter ended Sep 30, 2026, revenue was $3.44B, up 11.8% from a year earlier, with a net margin of 19.0%.

Short interest was 4.3M shares at the Oct 15 settlement, down 5.3% from the prior report (1.7% of float, 3.4 days to cover).

Market cap$139.16B253.5M shares
Revenue · quarter$3.44B+11.8% YoY
Diluted EPS$2.56−39.0% YoY
P/E · TTM35.0×P/S 10.7×
Net margin19.0%Gross 84.7%
Dividend yieldNone
52-week range409.47 – 558.88−1.8% from high
Volume1.8M1.15× 20-day avg
Volatility · 60d28.4%Annualised
Short % of float1.7%3.4 days to cover
Net cash$1.81BCash $6.30B
Next earnings—Not scheduled
Split-adjusted performance
1W +3.7%1M +9.3%3M +13.4%6M +28.4%YTD +21.1%1Y +28.9%3Y +53.6%5Y +203.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum85
Revenue growth59
Net margin86
Value (low P/E)35
Size99

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short4.3M−5.3% vs prior
Days to cover3.4Settled Oct 15
% of float1.7%
Short vol. 10d61.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
VRTXVertex Pharmaceuticals$549.04+3.44%+28.4%+11.8%19.0%35.0$139.16B
BMYBristol-Myers Squibb$64.19+4.02%+13.4%+5.7%25.6%14.1$131.21BCompare
PFEPfizer$30.79+2.63%+16.1%+2.6%−1.6%40.5$175.49BCompare
ABTAbbott Laboratories$115.51+5.58%+33.8%+13.0%7.4%36.8$199.88BCompare
REGNRegeneron Pharmaceuticals$930.67−4.39%+29.1%+36.3%38.1%20.0$96.28BCompare
MRKMerck & Co.$150.36+3.93%+32.4%+5.1%−8.0%116.9$370.96BCompare
TEVATeva Pharmaceutical Industries Limited$41.85−0.14%+15.2%−0.8%−13.9%69.0$48.81BCompare
ABBVABBVIE$294.83+3.09%+43.8%+10.3%24.2%50.4$521.00BCompare
ZTSZOETIS$89.20+7.48%−19.8%−0.2%28.0%14.1$36.86BCompare

News about Vertex Pharmaceuticals

All news →
Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline ExpansionZacks Investment Research · 1d ago▲ PositiveAmgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug RevenueThe Motley Fool · Oct 27, 2026▲ PositiveVertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Zacks Investment Research · Oct 27, 2026▲ PositiveVertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's WhyZacks Investment Research · Oct 26, 2026NeutralVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · Oct 26, 2026▲ Positive

Quick answers

What does Vertex Pharmaceuticals do?
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally.
What is VRTX's market cap?
$139.16B, based on the Nov 4 close of $549.04.
What is VRTX's P/E ratio?
35.0× trailing-twelve-month earnings of $3.98B.
Does Vertex Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of VRTX is sold short?
4.3M shares, 1.7% of float, as of Oct 15, 2026.
What sector is VRTX in?
Healthcare, in the Pharmaceuticals industry.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

HQ: Boston, MA6,400 employeesListed Jul 31, 1991vrtx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology